weight loss drug

2025.06.17

15:02

A-share closing review: ChiNext Index closed down 0.36%; brain-computer interface concepts collectively strengthened

The three major A-share indexes collectively adjusted today. As of the close, the Shanghai Composite Index fell 0.04%, the Shenzhen Component Index fell 0.12%, the ChiNext Index fell 0.36%, and the Beijing Stock Exchange 50 Index fell 0.40%. The total market turnover was 1.2371 trillion yuan, a decrease of 6.4 billion yuan from the previous day. Nearly 3,000 stocks in the entire market were in the red. In terms of sector themes, brain-computer interface, oil and gas, digital currency, and solid-state battery sectors led the gains; weight loss drugs and IP economic sectors led the declines. On the market, brain-computer interface concepts led the gains, with Aipeng Medical, Nanjing Panda, Innovation Medical, and Rongtai Health hitting the daily limit. Digital currency concepts continued to be active, with Chuangshi Technology, Hengbao Shares, and Dongxin Heping hitting the daily limit. The oil and gas sector led the gains, with Tongyuan Petroleum, Shandong Molong, and Zhunyou shares hitting the daily limit. The weight loss drug sector led the decline, with Kexing Pharmaceutical falling more than 10%. IP economic concept stocks collectively adjusted, with Hals, Boxinglong, Deyi Cultural and Creative, and many other stocks falling more than 5%.

11:37

A-share midday review: The three major stock indexes fluctuated and adjusted, and the concept of brain-computer interface exploded

The three major A-share indices showed a weak and volatile trend in the morning. As of noon closing, the Shanghai Composite Index fell 0.19%, the Shenzhen Component Index closed flat, and the ChiNext Index fell 0.14%; the half-day turnover of the Shanghai and Shenzhen stock markets was 771.5 billion, a decrease of 16.6 billion from the previous trading day. On the market, the concept of brain-computer interface continued to be active, Aipeng Medical, Nanjing Panda, Innovation Medical, and Rongtai Health hit the daily limit. Oil and gas stocks opened low and went high, and the stablecoin concept and battery sectors led the gains. The film and television theater and weight loss drug sectors led the decline, the IP economy pulled back, and Hals hit the daily limit.

11:31

A-share midday review: Shanghai Composite Index fluctuated and adjusted, falling 0.19% in half a day; brain-computer interface concepts collectively exploded

The three major A-share indices collectively adjusted in the morning. As of midday, the Shanghai Composite Index fell 0.19%, the Shenzhen Component Index closed flat, the ChiNext Index fell 0.14%, and the Beijing Stock Exchange 50 Index rose. The market's half-day turnover was 790.2 billion yuan, down 15.3 billion yuan from the previous day. More than 3,000 stocks in the market were in the red. In terms of sector themes, brain-computer interface, oil and gas, digital currency, and solid-state battery sectors led the gains; weight loss drugs and IP economy sectors led the declines. On the market, brain-computer interface concepts led the gains, with Aipeng Medical, Nanjing Panda, Innovation Medical, and Rongtai Health hitting the daily limit. Digital currency concepts continued to be active, with Chuangshi Technology and Hengbao shares hitting the daily limit, and Lakala and Sifang Jingchuang rising by more than 10%. The solid-state battery sector led the gains, with Yinghe Technology and Keliyuan hitting the daily limit. The weight loss drug sector led the decline, with Sinovac Pharmaceutical falling by more than 10%. IP economy concept stocks collectively adjusted, with Hals, Boxinglong, Deyi Cultural and Creative and many other stocks falling by more than 5%.

2025.06.05

09:37

The three major A-share indices turned down at the beginning of trading

The three major A-share indices turned downward in early trading, with medical services, weight loss drugs and dairy sectors leading the decline.

09:36

The three major A-share indices turned downward in early trading, with medical services, weight loss drugs and dairy sectors leading the decline.

2025.06.03

21:45

Use of the diet pill Wegovy has risen 50% among American teenagers.

2025.05.26

20:21

Goldman Sachs adjusts its forecast for the size of the weight loss drug market and raises the market development potential outside the United States

Goldman Sachs previously predicted that the weight loss drug market would reach $130 billion by 2030, but now it has become $95 billion. Goldman Sachs also lowered its peak forecast for the U.S. weight loss drug market to $70 billion, while raising its peak forecast for the "non-U.S." market to $50 billion. Goldman Sachs emphasized that existing market participants and new entrants will still have significant growth opportunities.

2025.05.12

22:10

US President Trump: Discussed weight loss drugs with pharmaceutical companies. Weight loss drugs in the United States are expensive.

21:58

Novo Nordisk fell nearly 2%. Eli Lilly said Zepbound's weight loss effect is much better than Wegovy

Novo Nordisk fell nearly 2% to $64.5. On the news front, Eli Lilly announced that its weight loss drug Zepbound performed better than Novo Nordisk Wegovy in five weight loss goals in a comparative trial.

20:56

20:48

White House official: White House officials said diabetes and weight loss drugs are expected to be a focus.

2025.05.08

15:50

Dinglong Technology: The company is currently focused on the main business of cosmetic raw materials and special engineering materials, and has no products related to weight loss drugs.

2025.05.07

18:01

Weight Watchers files for bankruptcy, faces debt reduction

WW International Inc. has filed for bankruptcy to implement a creditor-backed plan that would cut about $1.15 billion in debt from its balance sheet. The company has struggled to compete with diet pills like Ozempic and has found it hard to convince customers that its programs are still worth their time in the face of those drugs. Weight Watchers reported a 9.7% drop in revenue in the first quarter of this year, a 14.2% drop in subscribers at the end of the period, and a net loss of $72.6 million.

14:50

Is it the first time that weight loss drugs are included in the essential medicines list? WHO responded: The relevant plan is being formulated and is expected to be released as early as August

There are rumors that "WHO plans to include weight loss drugs in the list of essential medicines for the treatment of adult obesity for the first time". In response, the World Health Organization (WHO) said that since 2022, WHO has been developing a set of new guidelines on obesity prevention, care and treatment for different age groups (children, adolescents and adults). At present, the guidelines on the use of GLP-1 RA and GLP-1 RA/GIP dual receptor agonists to treat adult obese patients are being fully developed in accordance with the procedures of the Guidelines Review Committee, and the final plan is expected to be issued in August or September 2025. The purpose of the guidelines is to clarify the clinical indications, applications and planning considerations of GLP 1 RAs, including how and when such drugs can be used as part of a chronic disease management model that includes clinical interventions and lifestyle interventions. In addition, the above drugs are currently being reviewed by the WHO Expert Committee on the Selection and Use of Essential Medicines. The review process of this expert committee is independent of the guideline development process and aims to evaluate whether multiple drugs should be included in the WHO Model List of Essential Medicines (EML) and the WHO Model List of Essential Medicines for Children (EMLc). The two lists provide guidance to national or regional procurement agencies to help them select medicines that meet the priority health needs of the population. The measures mark a major shift in global public health policy in responding to the obesity epidemic.

2025.05.06

11:12

A-share weight loss drug concepts continued to rise, Jinkai Biosciences hit the 20cm daily limit, Changshan Pharmaceutical rose more than 12%, Shengnuo Bio, Zhengguang Co., Ltd., and Dezhan Health rose.

Email Subscription

Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.

Weekly Highlights

                                    Air India flight returns after takeoff due to technical issues
                            2025-06-16

                                    Southbound funds made a large net purchase of 5.743 billion yuan today. In terms of Hong Kong Stock Connect (Shanghai), China Construction Bank and Meituan-W received net purchases of HK$1.108 billion and HK$493 million respectively; Xiaomi Group-W ranked first in net sales, with an amount of HK$1.489 billion; in terms of Hong Kong Stock Connect (Shenzhen), Meituan-W and Kangfang Biopharma received net purchases of HK$622 million and HK$206 million respectively; Xiaomi Group-W ranked first in net sales, with an amount of HK$391 million.
                            2025-06-16

                                    Arm (ARM.O): We are better than Nvidia on a wider range of platforms.
                            2025-06-12

                                    Lei Jun: Xiaomi Yu7 will be released at the end of June
                            2025-06-16

                                    Putin: Russia will create unmanned system forces as a separate branch of the military
                            2025-06-13